ELI LILLY & Co — Form SCHEDULE 13D
Filed July 30, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 8/100
What the filing says
Eli Lilly & Co filed a Schedule 13D on July 30, 2026 disclosing acquisition of beneficial ownership in Scribe Therapeutics, Inc., a Delaware-incorporated biological products company. The filing documents do not contain specific dollar amounts, share counts, percentages, or transaction details in the text provided—only the administrative header information and filing metadata are visible.
Why this rating
Schedule 13D filing suggests material ownership stake (≥5%) in Scribe, a biotech firm. Lacking specifics on deal size/ownership %, cannot assess relative to $807.9B Lilly market cap. Likely small transaction for Lilly's scale; routine M&A disclosure.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.